Replies to post #122188 on Biotech Values

[DewDiligence]

I presume from the PR that Eliquis hit all endpoints on an ITT basis; however, given the way JNJ and Bayer presented the Xarelto data, your question is a reasonable one to ask.

[DewDiligence]

I guess [Eliquis] results are on an ITT basis but we'll know that by Aug. as well.

The efficacy data for superiority relative to warfarin are on a strict ITT basis. The safety (bleeding) data are modified ITT, including all patients who received at least one dose.